To appraise the clinical and cost effectiveness of:Nivolumab in combination with rucaparib, docetaxel or enzalutamide within its marketing authorisation for prostate cancer
Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1619
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 July 2023 | Note - Note added to the project documents |
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 12 February 2020 | Note added to the project documents |
| 09 May 2019 | In progress. Referred 29 April 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual